Stockscreener 앱 받기
203.71
0.85%
1.71
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies? - Yahoo Finance
Baker Bros. Advisors (RVMD) discloses 11.4M-share position in Revolution Medicines - Stock Titan
Farallon funds disclose 13.6M-share RVMD stake in Schedule 13G/A filing - Stock Titan
Revolution Medicines (RVMD): Janus Henderson discloses 5.1% beneficial stake - Stock Titan
Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript - AOL.com
(RVMD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Revolution and BeOne Meds enter research pact - thepharmaletter.com
Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest. - Pluang
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target - Yahoo Finance
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers - The Manila Times
Revolution Medicines (RVMD) Stock Looks Strong On Returns But Expensive On Value - simplywall.st
Tema ETFs LLC Sells 26,443 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Handelsbanken Fonder AB Raises Stock Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines (RVMD) Stock Looks Rich On Fresh RAS Drug Demand - Yahoo Finance
Revolution Medicines (RVMD) Is Up 6.2% After BeOne-Funded Phase 3 RAS(ON) DealHas The Bull Case Changed? - Yahoo Finance
Revolution Medicines (RVMD) Looks Fairly Valued As BeOne Deal Expands Its Asia Reach - Yahoo Finance
Can Revolution Medicines (RVMD) Turn A New Ally Into Global Reach? - Yahoo Finance
BeOne and Revolution Medicines partner for oncology therapies - Pharmaceutical Business review -
BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies - Pharmaceutical Executive
REVOLUTION MEDICINES, INC. : TRUIST SECURITIES RAISES TARGET PRICE TO $231 FROM $210 - Bitget
Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month HighShould You Buy? - MarketBeat
Bank of America Corp DE Cuts Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
Revolution Medicines (RVMD) BeOne Deal Puts Its Valuation Back In Focus - simplywall.st
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
BeOne and Revolution Medicines partner on RAS(ON) inhibitor combinations in Asia - AllSci
Revolution Medicines stock rating reiterated at Buy by TD Cowen - Investing.com South Africa
BeOne Medicines and Revolution Medicines Partner on RAS(ON) Cancer Therapies - Oncodaily
Revolution Medicines, BeOne Medicines form collaboration on RAS cancer drug combinations - Bitget
BeOne Medicines And Revolution Medicines Announce Clinical Development And Regional Commercialization Collaboration - TradingView
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration - Business Wire
Revolution Medicines, Inc. (RVMD) Stock Analysis: A Biotech Powerhouse with a Bold Vision for Cancer Treatment - directorstalkinterviews.com
REVOLUTION MEDICINES, INC. : JP MORGAN RAISES TARGET PRICE TO $227 FROM $205 - Bitget
Why Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next - webull.com
Assenagon Asset Management S.A. Buys Shares of 200,486 Revolution Medicines, Inc. $RVMD - MarketBeat
LifeSci Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $291 - moomoo.com
Sei Investments Co. Cuts Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years - Sahm
'We're excited and ready to go': Fast-growing Revolution Medicines preps potential launch of blockbuster pancreatic cancer drug - The Business Journals
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $201 to $240 - Moomoo
High Risk, High Reward: Inside The Revolution Medicines Bull Case (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines nears commercial launch wi... - Pluang
Oppenheimer Adjusts PT on Revolution Medicines to $230 From $195, Maintains Outperform Rating - Moomoo
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View - TradingView
Revolution Medicines, Inc. Stock 12‑Month Price Target Raised to $216.4, Implies 10% Upside - TradingView
RBC Adjusts PT on Revolution Medicines to $203 From $182, Maintains Outperform Speculative Risk Rating - marketscreener.com
Needham & Company LLC Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $240.00 - MarketBeat
Quantinno Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines Inc (RVMD) (Q2 2026) Earnings Call Highligh - GuruFocus
Revolution Medicines Q2 Earnings Call Highlights - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Announces Earnings Results - MarketBeat
Revolution Medicines preps for pancreatic drug launch, boosting expected 2026 expenses - Endpoints News
Earnings call transcript: Revolution Medicines lifts spending outlook in Q2 2026 - Investing.com
Revolution Medicines, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Revolution Medicines falls on second quarter earnings miss By Investing.com - Investing.com Nigeria
Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings - 24/7 Wall St.
Revolution Medicines falls on second quarter earnings miss - Investing.com
Revolution Medicines, Inc. Q2 2026: Net loss $(644.4M), EPS $(3.06) — 10-Q Summary - TradingView
Revolution Medicines reports Q2 net loss $644.4M; cash and marketable securities $3.94B - TradingView
Revolution Medicines (Nasdaq: RVMD) widens loss as R&D spend and financing surge - Stock Titan
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress - Yahoo Finance
Revolution Medicines earnings in focus as FDA approval looms By Investing.com - Investing.com Nigeria
Revolution Medicines earnings in focus as FDA approval looms - Investing.com
2.40%
0.67%
자본화:
|
볼륨(24시간):